Goldman Sachs Group Inc Cyma Bay Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$555 Billion
Q1 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.63 - $24.47 $883,771 - $1.71 Million	69,974 Added 12.48%	630,735 $14.9 Million
Q3 2023 May 14, 2024	SELL	$10.86 - $17.62 $759,917 - $1.23 Million	-69,974 Reduced 11.09%	560,761 $8.36 Million
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $134,490 - $218,206	-12,384 Reduced 2.16%	560,761 $8.36 Million
Q2 2023 May 14, 2024	SELL	$7.47 - $10.95 $1.5 Million - $2.19 Million	-200,201 Reduced 25.89%	573,145 $6.28 Million
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $1.5 Million - $2.19 Million	-200,201 Reduced 25.89%	573,145 $6.28 Million

Q1 2023 May 14, 2024	BUY	$5.88 - $9.59 $4.05 Million - $6.6 Million	688,132 Added 807.53%	773,346 $6.74 Million
Q1 2023 May 11, 2023	BUY	$5.88 - $9.59 $4.05 Million - $6.6 Million	688,132 Added 807.53%	773,346 $6.74 Million
Q4 2022 May 14, 2024	SELL	$3.22 - $6.27 $481,415 - $937,415	-149,508 Reduced 63.7%	85,214 $534,000
Q4 2022 Feb 13, 2023	SELL	$3.22 - $6.27 $481,415 - $937,415	-149,508 Reduced 63.7%	85,214 $534,000
Q3 2022 May 14, 2024	SELL	$2.77 - $4.25 $56,289 - $86,364	-20,321 Reduced 7.97%	234,722 $822,000
Q3 2022 Nov 10, 2022	SELL	$2.77 - $4.25 $56,289 - $86,364	-20,321 Reduced 7.97%	234,722 $821,000
Q2 2022 May 14, 2024	SELL	$1.72 - $3.39 $646,190 - $1.27 Million	-375,692 Reduced 59.56%	255,043 $753,000
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $531,605 - $1.05 Million	-309,073 Reduced 54.79%	255,043 $753,000
Q1 2022 May 16, 2022	BUY	$2.77 - $3.64 $379,478 - $498,665	136,996 Added 32.07%	564,116 $1.75 Million
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $917,823 - $1.31 Million	284,156 Added 198.76%	427,120 $1.44 Million
Q3 2021 Nov 10, 2021	BUY	$3.47 - $4.42 $496,085 - $631,900	142,964 New	142,964 $522,000

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.88M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account